Innovative Fill/Finish Capabilities Selkirk Pharma’s investment in state-of-the-art equipment such as the Bausch and Stroebel VarioSys filler with SKAN isolator technology positions them as a reliable partner for large-scale injectable manufacturing, offering high-yield, GMP-compliant capabilities suitable for both clinical trials and commercial production.

Rapid Clinical Trial Support The launch of ClinFAST™ demonstrates Selkirk Pharma’s focus on providing fast, flexible fill/finish services for biotech and pharma companies accelerating clinical trials, creating opportunities for partnerships with innovative drug developers needing swift, compliant manufacturing solutions.

Growing Facility Expertise Recent investments amounting to $60M and the expansion of aseptic and fill/finish capacity highlight Selkirk’s commitment to scaling their manufacturing footprint, making them well-suited to handle increasing demand for injectable biologics and vaccines from emerging and established biotech companies.

Leadership & Funding Momentum With recent leadership changes and a $24M seed funding round, Selkirk Pharma is strategically positioning itself for growth and innovation, opening opportunities to collaborate on cutting-edge projects requiring reliable sterile manufacturing capacity.

Market Focus & Compliance Selkirk’s emphasis on harmonized GMP compliance with US FDA and EU regulations, combined with their focus on aseptic processing and regulatory support, makes them an attractive partner for companies seeking compliant manufacturing solutions for biologics, vaccines, and clinical trial materials.